Group items matching

in title, tags, annotations or url

We invite you to explore and discuss with world-renown physicians the importance of complete cerebral embolic protection with TAVR. Please join us for the Keystone Heart Lunch Symposium during TCT 2018where we will share current research on cerebral embolic debris during TAVR, progress of the US REFLECT trial using TriGUARD 3™, early US experience and commentary with TriGUARD 3™.

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

The cardiac procedures like heart bypass surgery or open heart surgery may lead to serious outcomes for the brain and nervous system. Researches have indicated that owing to the serious threat to the brain led by heart surgery, several preventive measures have been taken by doctors, including the use of cerebral embolic protection (CEP) devices.

The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation, and other cardiovascular procedures. The TriGuard™ and TriGUARD 3™ product pipelines are designed to help interventional cardiologists and electrophysiologists to preserve brain reserve in patients undergoing these procedures.

Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).

The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation, and other cardiovascular procedures. The TriGuard™ and TriGUARD 3™ product pipelines are designed to help interventional cardiologists and electrophysiologists to preserve brain reserve in patients undergoing these procedures.